vs
PERMA FIX ENVIRONMENTAL SERVICES INC（PESI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是PERMA FIX ENVIRONMENTAL SERVICES INC的1.9倍（$30.3M vs $15.7M），PERMA FIX ENVIRONMENTAL SERVICES INC净利率更高（-36.0% vs -221.3%，领先185.3%），REGENXBIO Inc.同比增速更快（43.0% vs 6.9%），PERMA FIX ENVIRONMENTAL SERVICES INC自由现金流更多（$-4.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.4%）
Perma-Fix环境服务公司是专业环境管理服务商，主打危险废物、放射性废物及混合废弃物的处理、加工与处置服务，客户覆盖美国联邦政府机构、核设施运营商及能源、制造、国防领域的工业客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PESI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.9倍
$15.7M
营收增速更快
RGNX
高出36.1%
6.9%
净利率更高
PESI
高出185.3%
-221.3%
自由现金流更多
PESI
多$48.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.7M | $30.3M |
| 净利润 | $-5.7M | $-67.1M |
| 毛利率 | 7.7% | — |
| 营业利润率 | -20.6% | -190.0% |
| 净利率 | -36.0% | -221.3% |
| 营收同比 | 6.9% | 43.0% |
| 净利润同比 | -62.2% | -31.2% |
| 每股收益（稀释后） | $-0.31 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PESIRGNX
| Q4 25 | $15.7M | $30.3M | ||
| Q3 25 | $17.5M | $29.7M | ||
| Q2 25 | $14.6M | $21.4M | ||
| Q1 25 | $13.9M | $89.0M | ||
| Q4 24 | $14.7M | $21.2M | ||
| Q3 24 | $16.8M | $24.2M | ||
| Q2 24 | $14.0M | $22.3M | ||
| Q1 24 | $13.6M | $15.6M |
净利润PESIRGNX
| Q4 25 | $-5.7M | $-67.1M | ||
| Q3 25 | $-1.8M | $-61.9M | ||
| Q2 25 | $-2.7M | $-70.9M | ||
| Q1 25 | $-3.6M | $6.1M | ||
| Q4 24 | $-3.5M | $-51.2M | ||
| Q3 24 | $-9.0M | $-59.6M | ||
| Q2 24 | $-4.0M | $-53.0M | ||
| Q1 24 | $-3.6M | $-63.3M |
毛利率PESIRGNX
| Q4 25 | 7.7% | — | ||
| Q3 25 | 14.6% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 4.0% | 70.2% | ||
| Q3 24 | 7.9% | 48.8% | ||
| Q2 24 | -9.3% | 52.5% | ||
| Q1 24 | -4.6% | 72.6% |
营业利润率PESIRGNX
| Q4 25 | -20.6% | -190.0% | ||
| Q3 25 | -10.7% | -176.3% | ||
| Q2 25 | -19.8% | -296.3% | ||
| Q1 25 | -26.8% | 13.6% | ||
| Q4 24 | -24.4% | -242.1% | ||
| Q3 24 | -15.5% | -256.6% | ||
| Q2 24 | -36.0% | -251.3% | ||
| Q1 24 | -32.8% | -408.8% |
净利率PESIRGNX
| Q4 25 | -36.0% | -221.3% | ||
| Q3 25 | -10.5% | -208.3% | ||
| Q2 25 | -18.6% | -331.8% | ||
| Q1 25 | -25.7% | 6.8% | ||
| Q4 24 | -23.7% | -241.3% | ||
| Q3 24 | -53.4% | -246.3% | ||
| Q2 24 | -28.2% | -237.7% | ||
| Q1 24 | -26.1% | -405.4% |
每股收益（稀释后）PESIRGNX
| Q4 25 | $-0.31 | $-1.30 | ||
| Q3 25 | $-0.10 | $-1.20 | ||
| Q2 25 | $-0.15 | $-1.38 | ||
| Q1 25 | $-0.19 | $0.12 | ||
| Q4 24 | $-0.23 | $-0.99 | ||
| Q3 24 | $-0.57 | $-1.17 | ||
| Q2 24 | $-0.27 | $-1.05 | ||
| Q1 24 | $-0.26 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $1.9M | — |
| 股东权益账面价值 | $50.1M | $102.7M |
| 总资产 | $88.0M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.04× | — |
8季度趋势，按日历期对齐
现金及短期投资PESIRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务PESIRGNX
| Q4 25 | $1.9M | — | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $2.0M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $2.5M | — |
股东权益PESIRGNX
| Q4 25 | $50.1M | $102.7M | ||
| Q3 25 | $55.4M | $161.5M | ||
| Q2 25 | $56.8M | $213.7M | ||
| Q1 25 | $59.2M | $274.2M | ||
| Q4 24 | $62.4M | $259.7M | ||
| Q3 24 | $42.4M | $301.4M | ||
| Q2 24 | $51.0M | $348.3M | ||
| Q1 24 | $36.2M | $390.7M |
总资产PESIRGNX
| Q4 25 | $88.0M | $453.0M | ||
| Q3 25 | $91.2M | $525.2M | ||
| Q2 25 | $90.2M | $581.0M | ||
| Q1 25 | $92.9M | $490.9M | ||
| Q4 24 | $97.2M | $466.0M | ||
| Q3 24 | $78.2M | $519.1M | ||
| Q2 24 | $87.0M | $569.4M | ||
| Q1 24 | $74.0M | $629.2M |
负债/权益比PESIRGNX
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.03× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-4.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | -26.9% | -174.0% |
| 资本支出强度资本支出/营收 | 13.4% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-15.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PESIRGNX
| Q4 25 | $-2.1M | $-52.3M | ||
| Q3 25 | $-4.6M | $-56.0M | ||
| Q2 25 | $-1.9M | $-49.3M | ||
| Q1 25 | $-2.1M | $33.6M | ||
| Q4 24 | $-3.3M | $-31.6M | ||
| Q3 24 | $-5.6M | $-40.5M | ||
| Q2 24 | $-1.3M | $-45.5M | ||
| Q1 24 | $-4.5M | $-55.5M |
自由现金流PESIRGNX
| Q4 25 | $-4.2M | $-52.8M | ||
| Q3 25 | $-5.8M | $-56.5M | ||
| Q2 25 | $-2.8M | $-49.7M | ||
| Q1 25 | $-2.6M | $32.6M | ||
| Q4 24 | $-4.5M | $-32.7M | ||
| Q3 24 | $-7.0M | $-40.9M | ||
| Q2 24 | $-1.9M | $-46.0M | ||
| Q1 24 | $-4.8M | $-56.0M |
自由现金流率PESIRGNX
| Q4 25 | -26.9% | -174.0% | ||
| Q3 25 | -33.3% | -189.9% | ||
| Q2 25 | -19.2% | -232.8% | ||
| Q1 25 | -18.9% | 36.6% | ||
| Q4 24 | -30.5% | -154.2% | ||
| Q3 24 | -41.7% | -168.9% | ||
| Q2 24 | -13.5% | -206.2% | ||
| Q1 24 | -35.0% | -358.5% |
资本支出强度PESIRGNX
| Q4 25 | 13.4% | 1.7% | ||
| Q3 25 | 6.7% | 1.7% | ||
| Q2 25 | 6.2% | 1.8% | ||
| Q1 25 | 3.8% | 1.2% | ||
| Q4 24 | 8.0% | 5.1% | ||
| Q3 24 | 8.2% | 1.3% | ||
| Q2 24 | 4.3% | 2.1% | ||
| Q1 24 | 1.8% | 3.6% |
现金转化率PESIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PESI
| Fixed Price | $11.4M | 73% |
| Services | $4.3M | 27% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
